GSK rolls out inhaler-recycling program
RESEARCH TRIANGLE PARK, N.C. — Several cities across the country will play host to a new program from one drug maker to recycle respiratory inhalers.
Calling it the first program of its kind in the pharmaceutical industry, GlaxoSmithKline announced Wednesday the Complete the Cycle program, which it announced last month and for which it is currently enrolling pharmacies. Inhalers usually go to landfills because they can’t be recycled by curbside recyclers.
The program will take place in Atlanta; Boston; Chicago; Dallas; Denver; Los Angeles; Milwaukee; Minneapolis; St. Paul, Minn.; New York; Philadelphia; Salt Lake City; San Francisco; Oakland, Calif.; Seattle; St. Louis; Anchorage, Alaska; Austin, Texas; Columbus, Ohio; Eugene, Ore.; Portland, Ore.; Grand Rapids, Mich.; Huntsville, Ala.; Jacksonville, Fla.; Kansas City, Mo.; Lexington, Ky.; Louisville, Ky.; Raleigh-Durham, N.C.; Richmond, Va.; and Syracuse, N.Y.
"The Complete the Cycle recycling program provides an in-store location for people to drop off empty GSK respiratory inhalers for shipment to a specialized recycler," GSK SVP respiratory business area Jorge Bartolome said. "GSK piloted the program earlier in five markets and collected nearly 2,700 inhalers. By expanding to 31 U.S. markets, we hope to recycle more than 100,000 empty GSK inhalers."
Ala. pharmacist appointed NCPA president for 2012-13
ALEXANDRIA, Va. — The National Community Pharmacists Association has a new crop of leaders for 2012-13, the group said Wednesday.
The new officers and board of directors, announced at the NCPA’s 114th Annual Convention and Trade Exposition, are the group’s governing body.
Anniston, Ala., pharmacy owner Donnie Calhoun was named NCPA president; he serves on the NCPA’s board of directors and is a national director for Pharmacist’s Mutual Insurance Company. He is also the 2012 president of the Alabama Board of Pharmacy, having previously served on the board of directors of the National Home Infusion Association and the Alabama Pharmacy Association.
"We congratulate Donnie Calhoun on becoming NCPA president," NCPA CEO B. Douglas Hoey said. "Whether at the local, state or federal level, Donnie has been an effective advocate for independent community pharmacists and the patients they serve."
In addition to Calhoun, the board of directors includes president-elect Mark Riley, Little Rock, Ark.; chairman Bradley Arthur, Buffalo, N.Y.; immediate past president Lonny Wilson, Oklahoma City; board member John Sherrer, Marietta, Ga.; Keith Hodges, Gloucester, Va.; DeAnn Mullins, Lynn Haven, Fla.; David Smith, Indiana, Pa.; and Bill Osborn, Miami, Okla.
The officers are first VP Brian Caswell, Baxter Springs, Kan.; second VP Michele Belcher, Grants Pass, Ore.; third VP Hugh Chancy, Hahira, Ga.; fourth VP Jeff Carson, San Antonio; and fifth VP Lea Wolsoncroft, Birmingham, Ala.
Wolsoncroft is the newest member to join the roster of pharmacy leaders for the NCPA and is the founder of Kids Meds Pharmacy, which specializes in drugs for children, the NCPA said.
Mylan hopes to stop Watson launch of diabetes drug
PITTSBURGH — Mylan is challenging a federal court decision ordering the Food and Drug Administration to allow Watson Pharmaceuticals to launch a generic diabetes drug, Mylan said.
The generic drug maker said it filed a motion in the U.S. District Court for the District of Columbia Tuesday to stay the court’s order, which called on the FDA to let Watson launch a generic version of Takeda’s Type 2 diabetes drug Actos (pioglitazone).
"Mylan is disappointed in yesterday’s ruling regarding pioglitazone, and we believe the court erred in its decision by directly contravening the Hatch-Waxman Act," Mylan CEO Heather Bresch said, referring to the 1984 law that created an abbreviated approval pathway for generic pharmaceutical drugs. "Mylan does not believe Watson is entitled to participate in Mylan’s 180-day exclusivity period in relation to this product, and we intend to pursue this case vigorously, including seeking expedited relief from the appellate court if necessary."
Watson filed suit against the FDA in August 2012, alleging that an agency decision to deny Watson’s claim to shared exclusivity in marketing a generic version of Actos would improperly delay its launch of the drug.
Actos had sales of about $2.7 billion during the 12-month period ended in May, according to IMS Health.